ERBB2 and breast cancer: In a HER2+ BC subpopulation, high overall T cells (CD3+) and high cytotoxic T cells (CD8+) were positively associated with pCR rates after anthracycline+taxane-based neoadjuvant treatment, while a positive association between CD8+ TILs and pCR was described in HER2+ BC patients receiving anti-HER2-based neoadjuvant treatment.